Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models

2010 ◽  
Vol 56 (12) ◽  
pp. 1003-1010 ◽  
Author(s):  
Qin Wang ◽  
Xiao-jun Hou ◽  
Kun Cai ◽  
Tao Li ◽  
Yue-nan Liu ◽  
...  
Keyword(s):  
Shiga Toxin ◽  
Protective Efficacy ◽  
Wide Spectrum ◽  
Egg Yolk ◽  
Chromatography Method ◽  
In Vivo Experiments ◽  
Enteric Diseases ◽  
Uremic Syndrome

Shiga toxins produced by Escherichia coli O157:H7 cause a wide spectrum of enteric diseases, such as lethal hemorrhagic colitis and hemolytic uremic syndrome. In this study, the B subunit protein of Shiga toxin type 1 (Stx1) was produced in the E. coli system, was further purified by Ni-column Affinity Chromatography method, and was then used as an immunogen to immunize laying hens for yolk immunoglobulin (IgY) production. Titers of IgY increased gradually with boosting vaccination and, finally, reached a level of 105, remaining steady over 1 year. Then the protective efficacy of IgY against Stx1 was evaluated by in vitro and in vivo experiments. It was shown that the anti-Stx1 IgY could effectively block the binding of Stx1 to the Hela cells and could protect BALB/c mice from toxin challenges. The data indicates the facility of using egg yolk IgY as a therapeutic intervention in cases of Shiga toxin intoxication.

scholarly journals Shiga Toxin Subtypes Display Dramatic Differences in Potency

2011 ◽  
Vol 79 (3) ◽  
pp. 1329-1337 ◽  
Author(s):  
Cynthia A. Fuller ◽  
Christine A. Pellino ◽  
Michael J. Flagler ◽  
Jane E. Strasser ◽  
Alison A. Weiss
Keyword(s):  
Shiga Toxin ◽  
Vero Cells ◽  
Epidemiologic Studies ◽  
Systemic Complications ◽  
Animal Models Of Disease ◽  
Uremic Syndrome ◽  
Models Of Disease ◽  
Relative Potencies

ABSTRACTPurified Shiga toxin (Stx) alone is capable of producing systemic complications, including hemolytic-uremic syndrome (HUS), in animal models of disease. Stx includes two major antigenic forms (Stx1 and Stx2), with minor variants of Stx2 (Stx2a to -h). Stx2a is more potent than Stx1. Epidemiologic studies suggest that Stx2 subtypes also differ in potency, but these differences have not been well documented for purified toxin. The relative potencies of five purified Stx2 subtypes, Stx2a, Stx2b, Stx2c, Stx2d, and activated (elastase-cleaved) Stx2d, were studiedin vitroby examining protein synthesis inhibition using Vero monkey kidney cells and inhibition of metabolic activity (reduction of resazurin to fluorescent resorufin) using primary human renal proximal tubule epithelial cells (RPTECs). In both RPTECs and Vero cells, Stx2a, Stx2d, and elastase-cleaved Stx2d were at least 25 times more potent than Stx2b and Stx2c.In vivopotency in mice was also assessed. Stx2b and Stx2c had potencies similar to that of Stx1, while Stx2a, Stx2d, and elastase-cleaved Stx2d were 40 to 400 times more potent than Stx1.

scholarly journals Influenza prevention and treatment by passive immunization.

2014 ◽  
Vol 61 (3) ◽  
Author(s):  
Barbara Kalenik ◽  
Róża Sawicka ◽  
Anna Góra-Sochacka ◽  
Agnieszka Sirko
Keyword(s):  
Neutralizing Antibodies ◽  
Passive Immunization ◽  
Egg Yolk ◽  
Passive Immunity ◽  
Protective Effects ◽  
In Vivo Experiments ◽  
Effective Care ◽  
Antibody Preparations

Passive immunity is defined as a particular antigen resistance provided by external antibodies. It can be either naturally or artificially acquired. Natural passive immunization occurs during pregnancy and breast-feeding in mammals and during hatching in birds. Maternal antibodies are passed through the placenta and milk in mammals and through the egg yolk in birds. Artificial passive immunity is acquired by injection of either serum from immunized (or infected) individuals or antibody preparations. Many independent research groups worked on selection, verification and detailed characterization of polyclonal and monoclonal antibodies against the influenza virus. Numerous antibody preparations were tested in a variety of in vitro and in vivo experiments for their efficacy to neutralize the virus. Here, we describe types of antibodies tested in such experiments and their viral targets, review approaches resulting in identification of broadly neutralizing antibodies and discuss methods used to demonstrate their protective effects. Finally, we shortly discuss the phenomenon of maternal antibody transfer as a way of effective care for young individuals and as an interfering factor in early vaccination.

scholarly journals Monoclonal Immunoglobulin G1 Directed against Aspergillus fumigatus Cell Wall Glycoprotein Protects against Experimental Murine Aspergillosis

2005 ◽  
Vol 12 (9) ◽  
pp. 1063-1068 ◽  
Author(s):  
Ashok K. Chaturvedi ◽  
A. Kavishwar ◽  
G. B. Shiva Keshava ◽  
P. K. Shukla
Keyword(s):  
Cell Wall ◽  
Aspergillus Fumigatus ◽  
Protective Efficacy ◽  
Wide Spectrum ◽  
Kidney Tissue ◽  
Survival Times ◽  
Fungal Cell ◽  
New Strategy

ABSTRACT Most of the biological functions related to pathogenicity and virulence reside in the fungal cell wall, which, being the outermost part of the cell, mediates the host-fungus interplay. For these reasons much effort has focused on the discovery of useful inhibitors of cell wall glucan, chitin, and mannoprotein biosynthesis. In the absence of a wide-spectrum, safe, and potent antifungal agent, a new strategy for antifungal therapy is directed towards the development of monoclonal antibodies (MAbs). In the present study the MAb A9 (immunoglobulin G1 [IgG1]) was identified from hybridomas raised in BALB/c mice immunized with cell wall antigen of Aspergillus fumigatus. The immunoreactive epitopes for this IgG1 MAb appeared to be associated with a peptide moiety, and indirect immunofluorescence microscopy revealed its binding to the cell wall surface of hyphae as well as with swollen conidia. MAb A9 inhibited hyphal development as observed by MTT [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (25.76%), reduced the duration of spore germination, and exerted an in vitro cidal effect against Aspergillus fumigatus. The in vivo protective efficacy of MAb A9 was also evaluated in a murine model of invasive aspergillosis, where a reduction in CFU (>4 log10 units) was observed in kidney tissue of BALB/c mice challenged with A. fumigatus (2 × 105 CFU/ml) and where enhanced mean survival times (19.5 days) compared to the control (7.1 days) and an irrelevant MAb (6.1 days) were also observed.

Nano-Bio-Cogno Model of Acoustic Patterning for Molecular Neurostimulation

2013 ◽  
Author(s):  
Elena Lacatus ◽  
Alexandru Florin Savulescu
Keyword(s):  
Neural Activity ◽  
Interdisciplinary Research ◽  
Wide Spectrum ◽  
Acoustic Stimuli ◽  
In Vivo Experiments

To define a nano-bio-cogno model able to relate acoustic patterning on crystallization of biocompatible colloids to electrolytic molecular neurostimulation, means to functionally relate the in vitro and in vivo experiments aiming to find the key towards some objectively personalized therapies. For this interdisciplinary research, from the wide spectrum of acoustic frequencies were selected the biologically safe values for in vitro and in vivo experiments, aiming to define a possible relationships between the crystallization patterns of biocompatible colloidal electrolytes and the dynamics of neural activity under the influence of the same acoustic stimuli.

scholarly journals Efficacy Assessment of an Uncharged Reactivator of NOP-Inhibited Acetylcholinesterase Based on Tetrahydroacridine Pyridine-Aldoxime Hybrid in Mouse Compared to Pralidoxime

Biomolecules ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 858 ◽  
Author(s):  
André-Guilhem Calas ◽  
Anne-Sophie Hanak ◽  
Nina Jaffré ◽  
Aurélie Nervo ◽  
José Dias ◽  
...  
Keyword(s):  
Organophosphorus Compounds ◽  
Protective Efficacy ◽  
Wide Spectrum ◽  
Endothelial Permeability ◽  
Chemical Warfare Agents ◽  
Cholinesterase Inhibition ◽  
Adverse Effect Level ◽  
Warfare Agents

(1) Background: Human exposure to organophosphorus compounds employed as pesticides or as chemical warfare agents induces deleterious effects due to cholinesterase inhibition. One therapeutic approach is the reactivation of inhibited acetylcholinesterase by oximes. While currently available oximes are unable to reach the central nervous system to reactivate cholinesterases or to display a wide spectrum of action against the variety of organophosphorus compounds, we aim to identify new reactivators without such drawbacks. (2) Methods: This study gathers an exhaustive work to assess in vitro and in vivo efficacy, and toxicity of a hybrid tetrahydroacridine pyridinaldoxime reactivator, KM297, compared to pralidoxime. (3) Results: Blood–brain barrier crossing assay carried out on a human in vitro model established that KM297 has an endothelial permeability coefficient twice that of pralidoxime. It also presents higher cytotoxicity, particularly on bone marrow-derived cells. Its strong cholinesterase inhibition potency seems to be correlated to its low protective efficacy in mice exposed to paraoxon. Ventilatory monitoring of KM297-treated mice by double-chamber plethysmography shows toxic effects at the selected therapeutic dose. This breathing assessment could help define the No Observed Adverse Effect Level (NOAEL) dose of new oximes which would have a maximum therapeutic effect without any toxic side effects.

scholarly journals Melatonin: an anti-tumor agent for osteosarcoma

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Hadis Fathizadeh ◽  
Hamed Mirzaei ◽  
Zatollah Asemi
Keyword(s):  
Wide Spectrum ◽  
Antioxidant Properties ◽  
Bone Cancer ◽  
Therapeutic Approaches ◽  
In Vivo Experiments ◽  
Anti Cancer ◽  
Physiological Regulator ◽  
Tumor Agent

AbstractOsteosarcoma is the most common bone tumors which consisted of malignant mesenchymal cells generating osteoid and immature bone. It has been showed that osteosarcoma is common in children and adolescents and shows high mortality rate. A variety of therapeutic approaches (i.e., resection surgery, combined with chemotherapy and radiotherapy) have been used as conventional treatments in patients with osteosarcoma. Despite several attempts to improve therapeutic response, the rate of survival for osteosarcoma has not changed during the past 3 decades. Therefore, the discovery and developing new effective therapeutic platforms are required. Along to the established anti-cancer agents, some physiological regulators such melatonin, have been emerged as new anti-cancer agents. Melatonin is an indolamine hormone which is secreted from the pineal glands during the night and acts as physiological regulator. Given that melatonin shows a wide spectrum anti-tumor impacts. Besides different biologic activities of melatonin (e.g., immunomodulation and antioxidant properties), melatonin has a crucial role in the formation of bones, and its deficiency could be directly related to bone cancers. Several in vitro and in vivo experiments evaluated the effects of melatonin on osteosarcoma and other types of bone cancer. Taken together, the results of these studies indicated that melatonin could be introduced as new therapeutic candidate or as adjuvant in combination with other anti-tumor agents in the treatment of osteosarcoma. Herein, we summarized the anti-tumor effects of melatonin for osteosarcoma cancer as well as its mechanism of action.

scholarly journals Refrigeration of eggs influences the virulence of Salmonella Typhimurium

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Samiullah Khan ◽  
Andrea R. McWhorter ◽  
Talia S. Moyle ◽  
Kapil K. Chousalkar
Keyword(s):  
Bacterial Load ◽  
Egg Yolk ◽  
The United States ◽  
In Vivo Experiments ◽  
Genes Expression ◽  
Egg Storage ◽  
Storage Temperatures

AbstractSalmonella Typhimurium is a human pathogen associated with eggs and egg-derived products. In Australia, it is recommended that eggs should be refrigerated to prevent condensation that can enhance bacterial penetration across the eggshell. Except for the United States, the guidelines on egg refrigeration are not prescriptive. In the current study, in-vitro and in-vivo experiments were conducted to understand the role of egg storage temperatures (refrigerated vs ambient) on bacterial load and the virulence genes expression of Salmonella Typhimurium. The in-vitro egg study showed that the load of Salmonella Typhimurium significantly increased in yolk and albumen stored at 25 °C. The gene expression study showed that ompR, misL, pefA, spvA, shdA, bapA, and csgB were significantly up-regulated in the egg yolk stored at 5 °C and 25 °C for 96 h; however, an in-vivo study revealed that mice infected with egg yolk stored at 25 °C, developed salmonellosis from day 3 post-infection (p.i.). Mice fed with inoculated egg yolk, albumen, or eggshell wash stored at refrigerated temperature did not show signs of salmonellosis during the period of the experiment. Data obtained in this study highlighted the importance of egg refrigeration in terms of improving product safety.

ANTITUMOR EFFECT OF COLLOIDAL SILVER BISILICATE IN EXPERIMENTAL IN VITRO AND IN VIVO STUDIES

2019 ◽  
Vol 65 (5) ◽  
pp. 760-765
Author(s):  
Margarita Tyndyk ◽  
Irina Popovich ◽  
A. Malek ◽  
R. Samsonov ◽  
N. Germanov ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Growth ◽  
Tumor Cells ◽  
Human Tumor ◽  
Significant Inhibition ◽  
In Vivo Studies ◽  
Ehrlich Carcinoma ◽  
In Vivo Experiments

The paper presents the results of the research on the antitumor activity of a new drug - atomic clusters of silver (ACS), the colloidal solution of nanostructured silver bisilicate Ag6Si2O7 with particles size of 1-2 nm in deionized water. In vitro studies to evaluate the effect of various ACS concentrations in human tumor cells cultures (breast cancer, colon carcinoma and prostate cancer) were conducted. The highest antitumor activity of ACS was observed in dilutions from 2.7 mg/l to 5.1 mg/l, resulting in the death of tumor cells in all studied cell cultures. In vivo experiments on transplanted Ehrlich carcinoma model in mice consuming 0.75 mg/kg ACS with drinking water revealed significant inhibition of tumor growth since the 14th day of experiment (maximally by 52% on the 28th day, p < 0.05) in comparison with control. Subcutaneous injections of 2.5 mg/kg ACS inhibited Ehrlich's tumor growth on the 7th and 10th days of the experiment (p < 0.05) as compared to control.

Sign in / Sign up

Export Citation Format

Share Document